Aptahem AB (publ) (NGM:APTA)

Market Cap	20.03M
Revenue (ttm)	3.33M
Net Income (ttm)	-7.85M
Shares Out	17.26M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,174
Average Volume	30,088
Open	1.160
Previous Close	1.105
Day's Range	1.140 - 1.160
52-Week Range	0.560 - 4.500
Beta	0.37
RSI	50.76
Earnings Date	Aug 28, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.